Stockhouse.com uses cookies on this site. By continuing to use our service, you agree to our use of cookies. Cookies are used to offer you a better browsing experience and to analyze our traffic. We also use them to share usage information with our partners. See full details.
I Agree
×
Join today and have your say! It’s FREE!

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Please Try Again
{{ error }}
By providing my email, I consent to receiving investment related electronic messages from Stockhouse.

or

Privacy Policy | Disclaimer

Sign In

Please Try Again
{{ error }}
Password Hint : {{passwordHint}}
Forgot Password?

or

Privacy Policy | Disclaimer
Please Try Again {{ error }}

Send my password

Return to Login
SUCCESS
An email was sent with password retrieval instructions. Please go to the link in the email message to retrieve your password.

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Quote  |  Bullboard  |  News  |  Opinion  |  Profile  |  Peers  |  Filings  |  Financials  |  Options  |  Price History  |  Ratios  |  Ownership  |  Insiders  |  Valuation

Breaking & Recent News Clene Inc. CLNN

Healthcare Biotechnology

Recent & Breaking News (NDAQ:CLNN)

Clene Improves Cash Position and Runway by Securing New Debt Facility to Pay Off Existing Senior Loan

GlobeNewswire 7 days ago

FDA Provides Roadmap for Accelerated Approval Pathway Through Submission of Additional CNM-Au8® Biomarker Data in ALS

GlobeNewswire December 10, 2024

Clene Reports Third Quarter 2024 Financial Results and Recent Operating Highlights

GlobeNewswire November 13, 2024

Clene to Present at Upcoming October Conferences

GlobeNewswire October 9, 2024

Clene Announces Closing of $7.3 Million Registered Direct Offering and Concurrent Private Placements and Amendment of Debt Facility

GlobeNewswire October 1, 2024

Clene Announces $7.3 Million Registered Direct Offering and Concurrent Private Placements Priced at Market Under Nasdaq Rules

GlobeNewswire September 30, 2024

Clene Granted In-Person Meeting With FDA Senior Leadership to Discuss CNM-Au8 Biomarker and Related Clinical and Survival Data

GlobeNewswire September 16, 2024

Clene to Present at the H.C. Wainwright 26th Annual Global Investment Conference

GlobeNewswire September 3, 2024

Clene Reports Second Quarter 2024 Financial Results and Recent Operating Highlights

GlobeNewswire August 7, 2024

Clene Announces New CNM-Au8® Biomarker and Clinical Efficacy Data Submitted to FDA In Support of Treatment For ALS

GlobeNewswire August 6, 2024

Clene to Present at the Canaccord Genuity 44th Annual Growth Conference & Private Company Showcase

GlobeNewswire August 5, 2024

Clene to Present at the Emerging Growth Conference

GlobeNewswire July 12, 2024

Clene Announces Plans to Submit Briefing Book to the U.S. Food and Drug Administration in Connection with Granted Type C Interaction to Obtain FDA Feedback on Potential Pathway to Accelerated Approval for CNM-Au8® in ALS

GlobeNewswire July 11, 2024

Clene Announces 1-for-20 Reverse Stock Split

GlobeNewswire July 9, 2024

Clene to Present at H.C. Wainwright's 5th Annual Neuro Perspectives Virtual Conference

GlobeNewswire June 24, 2024

Clene Presents Preliminary Data for CNM-Au8® as a Potential Treatment for Rett Syndrome

GlobeNewswire June 21, 2024

Clene Presents Extended Survival Data Through 3.5 Years and New NfL Responder Results with CNM-Au8® 30 mg Treatment from the HEALEY ALS Platform Trial Open Label Extension at the 2024 ENCALS Meeting

GlobeNewswire June 18, 2024

Clene to Present at the Emerging Growth Conference

GlobeNewswire June 5, 2024

Clene Provides Update on Its NIH-Funded Expanded Access Program for CNM-Au8® in ALS (ACT-EAP)

GlobeNewswire May 28, 2024

Clene to Present at Upcoming May Conferences

GlobeNewswire May 14, 2024